Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized Phase 2 Study of ARQ 197 vs second-line chemotherapy in advanced gastric cancer
2007-004622-25Phase 2Terminated
- Sponsor
- ArQule
- Start
- Feb 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of tivantinib in gastric cancer (GC) (2 arms), sponsored by ArQule. Primary endpoints: Progression-free survival and Disease progression. Started Feb 2008; status: terminated.
02
Drugs
tivantinib
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on 2007-004622-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-004622-25.